EFNA1 and breast cancer: Similarly, Tandon et al. also employed ephrin-A1-expressing HAd-based vectors, and described in vivo ephrin-A1-EPHA2 interaction-mediated apoptosis in BC cells, as well as anticancer adaptive immune response activation, especially after combination with HAd-based vectors expressing the FMS-like tyrosine kinase receptor ligand (Flt3L) [32].